AT1 ASX · Health Care

Atomo Diagnostics Ltd

Announcements, last 12 months: 57
Price sensitive, last 12 months: 21
Followed on InvestorPA: Low (Outside the 20% most-followed companies on InvestorPA)

Upcoming events

Thu 5 Nov 2026, 10:00 AM AEDT

Atomo Diagnostics Limited - 2026 Annual General Meeting

Latest announcements

Released	Headline	Actions
2 Oct 2026, 8:40 AM	2026 Notice of Annual General Meeting
24 Sep 2026, 8:49 AM	FY26 Results and Strategy Presentation
21 Sep 2026, 8:53 AM	Atomo FY26 Results and Strategy Presentation
31 Aug 2026, 9:17 AM	2026 Appendix 4G and Corporate Governance Statement
31 Aug 2026, 9:15 AM	FY26 Results Presentation
31 Aug 2026, 9:13 AM	2026 Appendix 4E and Annual Report Price sensitive	AI summary
19 Aug 2026, 5:18 PM	Final Director's Interest Notice
19 Aug 2026, 9:55 AM	Managing Director & CEO Transition Price sensitive	AI summary
23 Jul 2026, 9:46 AM	Quarterly Activities/Appendix 4C Cash Flow Report Price sensitive	AI summary
21 Jul 2026, 9:16 AM	Investor Webinar Presentation

Sign in to see all AT1 announcements.

Guidance history

31 Aug 2026	Revenue increased by 41% to AUD 5,333,849; Loss from ordinary activities decreased by 29% to AUD 3,513,587
23 Jul 2026	FY26 total revenue: $5.3 million, Q4 FY26 revenue: $2.3 million, Cash on hand: $3.7 million
26 Feb 2026	Atomo anticipates a significant increase in demand from FebriDx in the coming years, noting that Lumos anticipates a decision from US FDA on FebriDx CLIA waiver during Q3 FY26. Lumos has previously disclosed significant contract demand for FebriDx, subject to securing CLIA waiver.

Sign in to see the full guidance history.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow AT1 to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.